Follistatin is a single-chain glycosylated protein that inhibits follicle stimulating hormone (FSH) release. Alternative splicing of Follistatin mRNA yields two isoforms, FS315 and FS288. FS315 is considered the main circulating form of Follistatin. Clone H10 recognizes an epitope on the C-terminal region of human Follistatin 315, allowing for detection of FSH levels using various analysis methods. ELISA experiments showed that H10 interacts with FS315 and does not interact with FS288. (McPherson, S.J. et al. 1999)
|Catalogue No.||Target||Research Areas||Applications||Size||Price (£)|
(raised to FS315)
Form in stock: IgG, purified – 1.0 mg/mL. Also available as unpurified supernatant.
Specificity: Synthetic peptide corresponding to sequence CDEDQDYSFPISSILEW of the C- terminal region of human Follistatin 315.
Human Histology positive control: Testis
Fusion partner: Spleen cells immunised from immunised Balb/c mice were fused with cells of the SP2/0 myeloma cell line.
Storage: Store at +4°C or -20°C. Avoid repeated freezing and thawing.
Shelf life: 18 months from date of dispatch.
Regulatory/ Restrictions: For research and commercial purposes.
- ⇓ Stephen J. McPherson, Sally L. Mellor, Hong Wang, Lee W. Evans, Nigel P. Groome, Gail P. Risbridger; Expression of Activin A and Follistatin Core Proteins by Human Prostate Tumor Cell Lines. Endocrinology 1999; 140 (11): 5303-5309.
- ⇓ Fitzgerald, A. M., Benz, C., Clark, A. F., & Wordinger, R. J. (2012). The Effects of Transforming Growth Factor-β2 on the Expression of Follistatin and Activin A in Normal and Glaucomatous Human Trabecular Meshwork Cells and Tissues. Investigative Ophthalmology & Visual Science, 53(11), 7358–7369.
- ⇓ Belinda Cancilla, Renea A Jarred, Hong Wang, Sally L Mellor, Gerald R Cunha, Gail P Risbridger, Regulation of Prostate Branching Morphogenesis by Activin A and Follistatin, Developmental Biology, Volume 237, Issue 1, 2001, Pages 145-158, ISSN 0012-1606.IHC-P, Dilution used 5 μg/mL
Clone PPG5/25 used to detect expression of ERβ5 in cancer tissue by IHC-P
Image caption: Immunoexpression of ERs in endometrial cancers. Tissues were classified as well (A-D), moderately (E-H) or poorly (J-M) differentiated; …immunoexpression of ERβ1, 2, 5 was readily detected (K. L, M). Inserts in panels K, L, and M show negative controls for ERβ1, ERβ2 and ERβ5 antibodies respectively generated using primary antibodies pre-absorbed with specific peptides used for immunisation. Asterisks (*) label the stromal compartment that was well defined in the well differentiated cancers. (Collins, F et al.)
Dilution used: 1:75
Clone H10 used to detect immunoreactivity with FS315 by IHC-P.
Immunolocalization of FS315 and FS288 to PC3 and LNCaP cell lines. Positive immunoreactivity for FS315 localized to the cytoplasm of the epithelial tumor cell lines LNCaP (A) and PC3 (B) using H10 antibody, no immunoreactivity was present if the antibody was preabsorbed with FS315 peptide (inset A, inset B). Mouse IgG antibody controls were negative (inset C, inset D). (McPherson, S.J. et al. 1999)
Concentration used: 6.75 μg/mL
Clone H10 used to detect expression of FS315 in TM cells by IHC-P
FST 315 expression in NTM (C) and GTM (G) tissues… (Fitzgerald, A et al.)
Dilution used: 1:100